Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have been given an average rating of “Buy” by the seven brokerages that are covering the stock, Marketbeat.com reports.

- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting ...

Rani Therapeutics Holdings, Inc. (RANI) stock price is 1.43 and Rani Therapeutics Holdings, Inc. (RANI) 10-day simple moving average is 1.36. Rani Therapeutics Holdings, Inc. (RANI) stock price is ...

On Friday, H.C. Wainwright adjusted its outlook on shares of Rani Therapeutics Holdings (NASDAQ:RANI), reducing the 12-month price target to $9 from the previous $13, while ...

1 Day RANI 0.72% DJIA -0.75% Russell 2K -0.86% Health Care/Life Sciences 0.29% ...

- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric ...